Clinical Trial Update: Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing salvage therapy with lenalidomide plus dexamethasone in patients with relapsed or refractory mantle cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: MANTLE CELL LYMPHOMA | Phase 2 | Status: COMPLETED